Investigational Site Number :1560007

Hangzhou 310009

0 studies enrolling now · 2 studies all time

What they study most

Breast Cancer, Non-relapsing Secondary Progressive Multiple Sclerosis

Studies at this site

• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early
• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) — Completed